These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23288242)

  • 41. Antidepressant response and subthreshold bipolarity in "unipolar" major depressive disorder: implications for practice and drug research.
    Rihmer Z; Dome P; Gonda X
    J Clin Psychopharmacol; 2013 Aug; 33(4):449-52. PubMed ID: 23775059
    [No Abstract]   [Full Text] [Related]  

  • 42. Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study.
    Rojas PS; Fritsch R; Rojas RA; Jara P; Fiedler JL
    Psychiatry Res; 2011 Sep; 189(2):239-45. PubMed ID: 21616544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis.
    Guico-Pabia CJ; Fayyad RS; Soares CN
    Int Clin Psychopharmacol; 2012 Jan; 27(1):1-7. PubMed ID: 21971533
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients.
    Zanardini R; Gazzoli A; Ventriglia M; Perez J; Bignotti S; Rossini PM; Gennarelli M; Bocchio-Chiavetto L
    J Affect Disord; 2006 Mar; 91(1):83-6. PubMed ID: 16448701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression.
    Nelson JC
    J Clin Psychopharmacol; 2011 Oct; 31(5):682-4. PubMed ID: 21881463
    [No Abstract]   [Full Text] [Related]  

  • 46. Epigenetic regulation of BDNF expression according to antidepressant response.
    Lopez JP; Mamdani F; Labonte B; Beaulieu MM; Yang JP; Berlim MT; Ernst C; Turecki G
    Mol Psychiatry; 2013 Apr; 18(4):398-9. PubMed ID: 22547115
    [No Abstract]   [Full Text] [Related]  

  • 47. Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study.
    Li Z; Zhang C; Fan J; Yuan C; Huang J; Chen J; Yi Z; Wang Z; Hong W; Wang Y; Lu W; Guan Y; Wu Z; Su Y; Cao L; Hu Y; Hao Y; Liu M; Yu S; Cui D; Xu L; Song Y; Fang Y
    Br J Psychiatry; 2014 Jul; 205(1):29-35. PubMed ID: 24764546
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anxious distress predicts subsequent treatment outcome and side effects in depressed patients starting antidepressant treatment.
    Gaspersz R; Lamers F; Kent JM; Beekman ATF; Smit JH; van Hemert AM; Schoevers RA; Penninx BWJH
    J Psychiatr Res; 2017 Jan; 84():41-48. PubMed ID: 27693981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
    Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
    Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
    [No Abstract]   [Full Text] [Related]  

  • 50. Effects of escitalopram on serum BDNF levels in elderly patients with depression: a preliminary report.
    Martocchia A; Curto M; Scaccianoce S; Comite F; Xenos D; Nasca C; Falaschi GM; Ferracuti S; Girardi P; Nicoletti F; Falaschi P
    Aging Clin Exp Res; 2014 Aug; 26(4):461-4. PubMed ID: 24435333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
    Inamdar A; Merlo-Pich E; Gee M; Makumi C; Mistry P; Robertson J; Steinberg E; Zamuner S; Learned S; Alexander R; Ratti E
    J Psychopharmacol; 2014 Jun; 28(6):570-81. PubMed ID: 24699061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum brain-derived neurotrophic factor level in dysthymia: a comparative study with major depressive disorder.
    Aydemir O; Deveci A; Taskin OE; Taneli F; Esen-Danaci A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1023-6. PubMed ID: 17433517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
    Ghosh R; Gupta R; Bhatia MS; Tripathi AK; Gupta LK
    Asian J Psychiatr; 2015 Dec; 18():37-41. PubMed ID: 26514447
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Major depressive disorders and BDNF (brain-derived neurotrophic factor)].
    Shimizu E; Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Jun; 24(3):147-50. PubMed ID: 15291244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum levels of brain-derived neurotrophic factor in comorbidity of depression and alcohol dependence.
    Umene-Nakano W; Yoshimura R; Ikenouchi-Sugita A; Hori H; Hayashi K; Ueda N; Nakamura J
    Hum Psychopharmacol; 2009 Jul; 24(5):409-13. PubMed ID: 19548207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study.
    Kim JM; Kim SW; Stewart R; Kim SY; Yoon JS; Jung SW; Lee MS; Yim HW; Jun TY
    Hum Psychopharmacol; 2011 Jan; 26(1):41-50. PubMed ID: 21344501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode.
    Karlović D; Serretti A; Jevtović S; Vrkić N; Serić V; Peleš AM
    J Psychiatr Res; 2013 Feb; 47(2):162-7. PubMed ID: 23102630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as diagnostic biomarkers for major depressive disorder and bipolar disorder.
    Hashimoto K
    Eur Arch Psychiatry Clin Neurosci; 2015 Feb; 265(1):83-4. PubMed ID: 25362578
    [No Abstract]   [Full Text] [Related]  

  • 59. Increased platelet count after treatment with venlafaxine or mirtazapine in depressed patients.
    Gronau W; Paslakis G; Lederbogen F; Weber-Hamann B; Gilles M; Schilling C; Deuschle M
    Pharmacopsychiatry; 2015 Jan; 48(1):37-9. PubMed ID: 25402815
    [No Abstract]   [Full Text] [Related]  

  • 60. Instability of depression severity at intake as a moderator of outcome in the treatment for major depressive disorder.
    Zilcha-Mano S; Barber JP
    Psychother Psychosom; 2014; 83(6):382-3. PubMed ID: 25323818
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.